Huaren Pharmaceutical Co., Ltd. (SHE:300110)

Market Cap	3.25B -19.4%
Revenue (ttm)	1.30B +8.0%
Net Income	-471.69M
EPS	-0.40
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,461,164
Open	3.050
Previous Close	2.730
Day's Range	2.590 - 3.050
52-Week Range	2.410 - 3.980
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and bulk preparations comprising sodium chloride, glucose, glucose and sodi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,549
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300110

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error